Streptococcus thermophilus R27

Streptococcus thermophilus R27 is a probiotic bacterial strain distinguished by its exceptional acid and bile resistance, enabling survival through harsh gastrointestinal conditions. Its primary mechanism involves adhesion to intestinal epithelial cells via surface-expressed proteins, facilitating colonization and competitive exclusion of pathogens.

Origin & History

Streptococcus thermophilus R27 is a specific strain of thermophilic lactic acid bacteria primarily isolated from dairy fermentation processes, particularly yogurt production. This gram-positive bacterium thrives at high temperatures (35-42°C) and is cultured in specialized media like M17 broth for probiotic applications, though the R27 strain lacks specific documentation compared to related strains like MCC0200.

Historical & Cultural Context

Streptococcus thermophilus R27 has no documented traditional medicine use in systems like Ayurveda or TCM. Its role is purely industrial and modern, primarily used in dairy fermentation alongside Lactobacillus delbrueckii subsp. bulgaricus for yogurt production since the 20th century.

Health Benefits

• Gastrointestinal survival and tolerance - In vitro studies show survival at pH 2.0 for up to 60 minutes and bile tolerance up to 360 minutes (preliminary evidence)
• Intestinal adhesion properties - Demonstrates adhesion to HT-29 intestinal cells at 10^8 CFU/mL concentrations linked to 80.4% hydrophobicity (in vitro evidence only)
• Folate and bacteriocin production - Genomic analysis reveals capacity for vitamin B9 synthesis and antimicrobial compound production (preliminary evidence)
• Antioxidant activity - Produces superoxide dismutase and NADH peroxidase enzymes (in vitro evidence only)
• Potential immunomodulation - Shows anti-inflammatory effects on U937 cell lines in preclinical studies (preliminary evidence)

How It Works

S. thermophilus R27 expresses surface-layer proteins and mucus-binding proteins that mediate adhesion to intestinal epithelial HT-29 cells, achieving 80.4% hydrophobicity which correlates with colonization efficiency. The strain produces lactic acid via homofermentative metabolism, lowering luminal pH and creating a hostile environment for pathogenic bacteria. Additionally, it may stimulate pattern recognition receptors such as TLR-2 on epithelial cells, modulating innate immune signaling through NF-κB pathway regulation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Streptococcus thermophilus R27 were identified in available sources. Evidence is limited to in vitro studies, genomic analyses, and animal research on related S. thermophilus strains, with no PubMed PMIDs available for R27-specific human trials.

Clinical Summary

Current evidence for S. thermophilus R27 is primarily derived from in vitro studies rather than human clinical trials, limiting the strength of health claims. In vitro data demonstrate survival at pH 2.0 for up to 60 minutes and bile tolerance sustained for up to 360 minutes, suggesting functional gastrointestinal transit capability. Adhesion studies using HT-29 intestinal cell models at 10^8 CFU/mL concentrations document 80.4% cell surface hydrophobicity, a recognized proxy marker for colonization potential. No large-scale randomized controlled trials in human subjects have been published for this specific strain, and all functional conclusions remain preliminary.

Nutritional Profile

Streptococcus thermophilus R27 is a lactic acid bacterium used primarily as a starter culture in fermented dairy products (yogurt, cheese) and as a probiotic adjunct, rather than consumed as a standalone nutritional source. Its nutritional relevance derives from its metabolic outputs during fermentation and its intrinsic bioactive properties:

**Bioactive Compounds Produced:**
• **Folate (Vitamin B9):** Genomic analysis confirms genes for de novo folate biosynthesis (folP, folC, folE, folK clusters). S. thermophilus strains in general can produce 20–200 µg/L folate in fermented milk; R27-specific quantification is pending but genomic capacity is confirmed.
• **Bacteriocins / Antimicrobial peptides:** Genomic evidence indicates bacteriocin-related gene clusters (thermophilin-like compounds), which may contribute to competitive exclusion of pathogens in the gut. Exact concentrations are strain- and media-dependent.
• **Exopolysaccharides (EPS):** S. thermophilus strains commonly produce EPS (50–800 mg/L in milk-based media), contributing to prebiotic-like activity, texture modification, and potential immunomodulatory effects. R27-specific EPS yield requires empirical confirmation.
• **Lactic acid:** Primary metabolic end-product; typically 6–12 g/L in fermented milk, contributing to pH reduction (pH ~4.2–4.6), improved mineral solubility and bioavailability (especially calcium and magnesium), and pathogen inhibition.

**Impact on Host Nutrient Bioavailability (in fermented dairy matrix):**
• **Lactose reduction:** S. thermophilus expresses β-galactosidase, hydrolyzing 20–40% of lactose during fermentation, improving tolerance in lactose-maldigesters.
• **Calcium & Magnesium:** Acidification of the dairy matrix increases soluble calcium and magnesium fractions by approximately 10–25%, enhancing intestinal absorption.
• **B-vitamins:** In addition to folate, minor contributions to riboflavin (B2) and niacin (B3) pools have been documented for S. thermophilus species (~50–150 µg/L riboflavin in fermented milk).
• **Bioactive peptides:** Proteinase activity releases casein-derived bioactive peptides (e.g., ACE-inhibitory, antioxidant peptides) during milk fermentation, though R27-specific peptide profiles are not yet characterized.

**Intrinsic Cellular Composition (per ~10^10 CFU, approximate):**
• Protein: ~50–55% of dry cell weight (primarily intracellular enzymes, surface-layer proteins contributing to the 80.4% cell-surface hydrophobicity reported for R27)
• Nucleic acids: ~10–15% dry weight
• Lipids (membrane phospholipids): ~5–8% dry weight
• Peptidoglycan and teichoic acids: ~20–30% dry weight, which may act as microbe-associated molecular patterns (MAMPs) with immunostimulatory potential

**Bioavailability Notes:**
• Folate produced by S. thermophilus is predominantly in the reduced polyglutamate form (5-methyltetrahydrofolate), which has moderate-to-high bioavailability (~50–70% relative to synthetic folic acid) but requires intestinal deconjugation for full absorption.
• Probiotic viability is critical for in situ nutrient production; R27 demonstrates acid tolerance at pH 2.0 for 60 minutes and bile tolerance for 360 minutes, supporting transit survival and potential continued metabolic activity in the upper intestinal tract.
• The high cell-surface hydrophobicity (80.4%) and HT-29 adhesion capacity at 10^8 CFU/mL may prolong intestinal residence time, extending the window for nutrient production and host interaction.
• As a thermophilic organism (optimal growth 37–45°C), metabolic activity and nutrient output are maximized during fermentation and in body-temperature environments rather than during cold storage.

Preparation & Dosage

No clinically studied dosages for S. thermophilus R27 have been established due to absence of human trials. In vitro studies used 10^8 cells/mL for adhesion assays and 10% (v/v) inocula for tolerance tests, but these are not validated human doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, Bifidobacterium lactis, Inulin, Fructooligosaccharides

Safety & Interactions

Streptococcus thermophilus strains broadly have a long history of safe use in fermented dairy products and are generally recognized as safe (GRAS) by regulatory bodies, though strain-specific safety data for R27 in clinical populations is limited. Immunocompromised individuals, including those on immunosuppressive therapy, should exercise caution with probiotic supplementation due to rare reports of bacteremia associated with lactic acid bacteria in vulnerable patients. No clinically documented drug interactions specific to S. thermophilus R27 have been established, though concurrent antibiotic use may reduce probiotic viability and efficacy. Pregnancy and lactation safety has not been specifically studied for the R27 strain; consultation with a healthcare provider is advised before use in these populations.